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Abstract (200 words – limit of 200) 
Aims: Liver disease is highly prevalent among people with type 2 diabetes mellitus (T2DM). 
We evaluated the dipeptidyl peptidase-4 inhibitor linagliptin in subjects with T2DM and 
hepatic disorders. 
Methods: Data were pooled from 17 randomized, double-blind, placebo-controlled clinical 
trials of linagliptin in T2DM subjects that included individuals with self-reported history of 
hepatic disorders at baseline. The primary endpoint was change in HbA1c from baseline to 
week 24. 
Results: Of the 7009 participants (56% white, 39% Asian), 574 had hepatic disorders, most 
commonly hepatic steatosis (60%). At week 24, adjusted mean ± standard error (SE) change 
in HbA1c from baseline in those with hepatic disorders was –0.75% ± 0.05 with linagliptin 
and –0.20% ± 0.08 with placebo [treatment difference: –0.54% (95% confidence interval –
0.72 to –0.36); P<.0001]. There was no significant difference in HbA1c reduction between 
subjects with or without baseline hepatic disorders (P=.4042). Among subjects with hepatic 
disorders, 13.5% and 14.8% of the linagliptin and placebo groups, respectively, reported 
drug-related adverse events while 10.4% and 15.9%, respectively, reported hypoglycemia. 
Overall, adverse event rates were similar in individuals with or without hepatic disorders. 
Conclusions: This large pooled analysis suggests that linagliptin is effective and well 
tolerated in people with T2DM and liver disease. 
 
Keywords: Linagliptin, DPP-4 inhibitor, Type 2 diabetes, Liver disease, Pooled analysis, 
Efficacy, Safety 
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1. Introduction 
Diabetes is a leading cause of liver disease, and non-alcoholic fatty liver disease (NAFLD), in 
particular, may be one of its sequelae (Tolman et al., 2007; Yki-Järvinen, 2014). Conversely, 
liver disease may be a cause of diabetes (Tolman et al., 2007; Yamazaki et al., 2015; Yki-
Järvinen, 2014). Consequently, liver disease is prevalent amongst people with type 2 diabetes 
mellitus (T2DM). It is estimated that NAFLD affects approximately 70% (Cusi, 2009), and 
cirrhosis is a common cause of diabetes-related death (de Marco et al., 1999). Of note, more 
than 50% of people with diabetes live in the Western Pacific region (including China) and 
Southeast Asia (including India) (International Diabetes Federation 2015)– where liver 
disease is already highly prevalent (e.g., viral hepatitis, cirrhosis, hepatocellular carcinoma) 
(Bosetti et al., 2014) with NAFLD becoming increasingly common (Wong, 2013). 
The presence of liver disease complicates clinical decision-making in T2DM because 
the liver is essential to both glucose homeostasis and the metabolism and elimination of 
several glucose-lowering drugs. Consequently, a number of antihyperglycemic agents must 
be used cautiously, depending on the severity of hepatic impairment (Khan et al., 2012; 
Scheen, 2014a). Historically, the pharmacokinetics, efficacy and safety of older orally 
administered glucose-lowering drugs (i.e., sulfonylureas, meglitinides, metformin and 
thiazolidinediones) have not been extensively studied in the presence of liver disease (Khan 
et al., 2012; Scheen, 2014a). However, dosage reduction and/or cautious use in individuals 
with hepatic impairment is recommended for most of these agents due to the potential for 
lactic acidosis (metformin), hypoglycemia (sulfonylureas, meglitinides) or liver injury (with 
pioglitazone, the remaining widely used thiazolidinedione). Because of these potential 
limitations, the efficacy and safety of new glucose-lowering agents, including dipeptidyl 
peptidase (DPP)-4 inhibitors, in people with T2DM and liver disease are of considerable 
importance. 
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Linagliptin is a DPP-4 inhibitor that is excreted mainly in feces via enterohepatic 
pathways; i.e., bile and direct excretion into the gut (Blech et al., 2010; Fuchs et al., 2012). 
However, hepatic metabolism plays only a minor role in the enterohepatic excretion of 
linagliptin, with over 80% of the administered dose excreted as parent compound (Graefe-
Mody et al., 2012a). Despite the involvement of the liver in excretion of linagliptin, hepatic 
impairment does not have clinically relevant effects on its pharmacokinetics, even the 
presence of severe hepatic impairment based on Child–Pugh classification (Graefe-Mody et 
al., 2012b). This may be because of the very high affinity of linagliptin for DPP-4, which is 
present in plasma, resulting in high plasma protein binding (99% at concentrations below 1 
nmol/l in in vitro assays (Fuchs et al., 2009)) and, therefore, very low plasma concentrations 
of free linagliptin (~0.7 nmol/l) (Graefe-Mody et al., 2012b). Even subjects with severe 
hepatic impairment may have sufficient residual liver function to eliminate this small amount 
of free linagliptin, and, therefore, dose adjustment of linagliptin is not advocated for hepatic 
impairment (Boehringer Ingelheim Pharmaceuticals Inc., 2013b; McGill et al., 2013). As 
linagliptin is not substantially excreted by the kidneys (<5%), no dose adjustment is required 
in individuals with chronic kidney disease (Boehringer Ingelheim Pharmaceuticals Inc., 
2013b; Graefe-Mody et al., 2011; McGill et al., 2013), in contrast to other members of this 
class of drugs (Scheen, 2015). 
No randomized controlled study of the glycemic efficacy and tolerability of 
linagliptin, or any other DPP-4 inhibitor, has been conducted exclusively in people with both 
T2DM and liver disease; however, many such individuals participated in several late-stage 
clinical trials of linagliptin. We have therefore conducted a retrospective pooled analysis of 
T2DM patients with known liver disease at baseline from these studies in order to examine 
the efficacy and tolerability of linagliptin in this population. 
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2. Methods 
2.1. Study design and patient population 
This was a retrospective pooled analysis of participant-level data from all randomized, 
double-blind, placebo-controlled Phase II or III clinical trials of linagliptin that lasted for at 
least 12 weeks, included individuals with pre-existing hepatic disorders, and had results 
available by January 2013. Subjects with T2DM were defined as having hepatic disorders if 
they had a concomitant diagnosis or adverse event at baseline that was classified within the 
Standardized Medical Query (SMQ) “hepatic disorders” from the Medical Dictionary for 
Regulatory Activities (MedDRA) version 15.1. Seventeen studies met these criteria (Bajaj et 
al., 2014; Barnett et al., 2013; Barnett et al., 2012; Chen et al., 2015; Del Prato et al., 2011; 
Gomis et al., 2011; Haak et al., 2012; Kawamori et al., 2012; Laakso et al., 2015; Lewin et 
al., 2012; McGill et al., 2013; Owens et al., 2011; Ross et al., 2012; Taskinen et al., 2011; 
Thrasher et al., 2014; Wang et al., 2015; Yki-Järvinen et al., 2013); these studies had 
compared linagliptin with placebo as monotherapy or added to other glucose-lowering drugs 
in a variety of patient populations (Table S1), with study durations ranging from 12 to 52 
weeks. 
In general, these studies included T2DM subjects aged ≥18 years with inadequate 
glycemic control, typically glycated hemoglobin (HbA1c) ≥7.0 to ≤10.0% (≥53 to ≤86 
mmol/mol). Subjects who had experienced a recent myocardial infarction, stroke or transient 
ischemic attack were excluded. Also excluded were those with impaired hepatic function at 
screening, which was defined as serum concentration of alanine transaminase (ALT), 
aspartate transaminase (AST) or alkaline phosphatase (ALP) more than three times the upper 
limit of normal (ULN). However, individuals known to have liver disease were permitted to 
participate provided their hepatic function at screening satisfied the above criteria. 
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The primary endpoint in these studies was change from baseline in HbA1c, usually 
after 24 weeks, with other parameters such as changes from baseline in fasting plasma 
glucose (FPG), body weight, and tolerability assessed as secondary endpoints. 
 
2.2. Assessments 
In this pooled analysis, the primary efficacy parameter was change from baseline in HbA1c 
after 24 weeks. Other parameters evaluated were change from baseline in HbA1c over time, 
change from baseline in HbA1c at week 24 in subgroups according to duration of T2DM, 
renal function and race, and change from baseline in FPG at week 24. Changes in 
postprandial glucose, homeostasis model assessment of pancreatic β-cell function (HOMA-
%B), disposition index and body weight were also evaluated. Safety and tolerability 
assessments included the incidence of reported adverse events, which were classified using 
MedDRA version 15.1. A serious adverse event was defined as an event that was fatal, life-
threatening, required hospitalization or prolonged existing hospitalization, resulted in 
persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or was 
deemed serious for any other reason. Hypoglycemia was defined by investigators as a blood 
glucose concentration of ≤3.9 mmol/l (≤70 mg/dl) or an event requiring the assistance of 
another person to administer carbohydrate, glucagon or other resuscitative action. Pancreatitis 
was defined as the MedDRA preferred term of chronic pancreatitis or any preferred term 
within the Standardized MedDRA Query for pancreatitis from MedDRA version 17.0 (Table 
S2). Pancreatic cancer was defined based on a customized MedDRA query for pancreatic 
cancer-related preferred terms from MedDRA version 17.0 (Table S2). The results of 
laboratory tests in the individual studies, conducted by central laboratories, were also pooled 
and analyzed. 
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2.3. Statistical analyses 
Efficacy analyses were performed on the full-analysis set (FAS): all randomized subjects who 
received at least one dose of study drug and had a baseline HbA1c measurement and at least 
one on-treatment HbA1c measurement. Efficacy endpoints were compared between 
linagliptin and placebo using analysis of covariance (ANCOVA). Changes in HbA1c from 
baseline to week 24 and over time in the FAS were evaluated using a general ANCOVA 
model containing terms for treatment, study, continuous baseline HbA1c, prior use of oral 
anti-diabetes drugs, hepatic disorders, and hepatic disorders-by-treatment interaction. 
Efficacy measurements after start of glycemic rescue treatment were set to missing; those and 
other missing data were imputed using the last-observation-carried-forward (LOCF) method. 
Change from baseline in HbA1c for FAS (LOCF) subgroups for T2DM duration, 
renal function and race were analyzed using the general ANCOVA model but with additional 
terms: subgroup, hepatic disorders-by-subgroup-by-treatment interaction. Change from 
baseline in FPG at week 24 was analyzed for the FAS (LOCF) using the general ANCOVA 
model with an additional term for continuous baseline FPG. Change from baseline in 
postprandial glucose was analyzed using descriptive statistics for the subset of subjects who 
had undergone meal-tolerance tests at baseline and at week 24 in four of the reference 
studies. Changes from baseline in β-cell function (HOMA-%B) and disposition index were 
measured in nine and eight of the reference studies, respectively; data were pooled and 
analyzed for participants in the FAS of this subset who had available data (observed cases) 
using the general ANCOVA model with an additional term for continuous baseline HOMA-
%B or continuous baseline disposition index, respectively. The disposition index was 
calculated as the ratio of HOMA-%B over HOMA of insulin resistance: i.e., disposition index 
= 450/[FPG (mmol/l) × [FPG (mmol/l) − 3.5]]. Change from baseline in body weight at week 
24 was analyzed for subjects in the FAS with available data (observed cases); the general 
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ANCOVA model was used with the addition of continuous baseline body weight. Analyses 
of the subgroup of patients with baseline hepatic steatosis were conducted using the same 
models described above but with the term for hepatic disorders replaced by a term for hepatic 
steatosis. 
The incidence of participants with adverse events was summarized with descriptive 
statistics for the treated set: all randomized subjects who received at least one dose of study 
drug. In addition, data were adjusted for time exposed to study drug as the trials included had 
different durations. Laboratory data from liver function tests were also analyzed using 
descriptive statistics. 
 
3. Results 
3.1. Baseline characteristics and demographics 
This pooled analysis comprised 574 T2DM subjects with baseline hepatic disorders and 6435 
without. Most subjects were white or Asian, and baseline characteristics were generally 
similar between the linagliptin and placebo groups, with or without baseline hepatic disorders 
(Table 1). Among the former, hepatic steatosis was the most common condition (n=343), 
affecting approximately 60% of both the linagliptin group (230 of 385 subjects) and the 
placebo group (113 of 189 subjects) (Table S3). Seventeen subjects (3.0%) had hepatitis C. 
 
3.2. Efficacy 
Linagliptin was significantly more efficacious than placebo in reducing HbA1c. At week 24, 
the adjusted mean ± standard error (SE) change from baseline in subjects with baseline 
hepatic disorders was –0.75% ± 0.05 (−8.16 ± 0.60 mmol/mol) and –0.20% ± 0.08 (−2.24 ± 
0.84 mmol/mol) with linagliptin and placebo, respectively, a treatment difference of –0.54% 
[95% confidence interval (CI) –0.72 to –0.36; P<.0001]. The placebo-adjusted HbA1c 
10 
 
reduction with linagliptin was not significantly different between subjects with or without 
hepatic disorders (P=.4042) (Fig. 1). The largest HbA1c reductions occurred during the first 
12 weeks, after which time glycemic control remained stable (Fig. 2). In the subset of 
subjects with hepatic steatosis at baseline, the adjusted mean ± SE change from baseline in 
HbA1c after 24 weeks was –0.84% ± 0.09 (−9.22 ± 1.03 mmol/mol) with linagliptin and  
–0.28% ± 0.08 (−3.0 ± 1.31 mmol/mol) with placebo, a treatment difference of –0.57% 
(−6.19 mmol/mol) [95% CI –0.80 to –0.33 (−8.73 to −3.66); P<.0001]. 
Furthermore, linagliptin generally had significantly greater efficacy than placebo in 
reducing HbA1c irrespective of T2DM duration, renal function or race (Fig. 3). Although the 
placebo-adjusted reduction in HbA1c at week 24 was not significant in black subjects with 
hepatic disorders, this is likely a consequence of low statistical power in this subgroup 
because of the small number of subjects (n=14). In all subgroups, the magnitude of HbA1c 
reduction was not significantly affected by the presence or absence of hepatic disorders 
(P>.05 for all three-way interactions between treatment, hepatic disorders and T2DM 
duration, kidney disease or race) (Fig. 3). 
Linagliptin was also significantly more effective than placebo in reducing FPG. At 
week 24, the adjusted mean ± SE change from baseline in FPG in subjects with hepatic 
disorders was –0.60 ± 0.13 mmol/l and 0 ± 0.19 mmol/l with linagliptin and placebo, 
respectively, a treatment difference of –0.60 mmol/l (95% CI –1.04 to –0.16; P=.0071). In 
subjects without hepatic disorders, the adjusted mean ± SE change from baseline was –0.73 ± 
0.05 mmol/l and 0.09 ± 0.06 mmol/l with linagliptin and placebo, respectively, a treatment 
difference of –0.82 mmol/l (95% CI –0.95 to –0.69; P<.0001). At week 24, the adjusted mean 
± SE change from baseline in FPG in subjects with hepatic steatosis was –0.69 ± 0.24 mmol/l 
and −0.03 ± 0.31 mmol/l with linagliptin and placebo, respectively, a treatment difference of 
–0.66 mmol/l (95% CI –1.25 to –0.06; P=.0313). 
11 
 
Within the subset of subjects who underwent meal-tolerance testing, linagliptin 
treatment was associated with a reduction in 2-hour postprandial glucose whereas placebo 
treatment was associated with increased 2-hour postprandial glucose. At week 24 in subjects 
with hepatic disorders, mean ± standard deviation (SD) change from baseline in 2-hour 
postprandial glucose was –1.75 ± 3.67 mmol/l with linagliptin (n=17) compared with +3.98 ± 
1.17 mmol/l in those receiving placebo (n=3). In subjects without hepatic disorders, mean ± 
SD change in 2-hour postprandial glucose was –2.20 ± 3.63 mmol/l and +0.85 ± 3.62 mmol/l 
in those receiving linagliptin (n=149) or placebo (n=55), respectively. At week 24 in subjects 
with hepatic steatosis, mean ± SD change from baseline in 2-hour postprandial glucose was  
–1.23 ± 3.67 mmol/l with linagliptin (n=11) compared with +3.98 ± 1.17 mmol/l in those 
receiving placebo (n=3). 
Among subjects whose pancreatic β-cell function was estimated by HOMA-%B, 
improvement at 24 weeks was greater with linagliptin than placebo, but the difference was 
significant only in those without hepatic disorders: placebo-adjusted mean change from 
baseline in HOMA-%B with linagliptin of 5.51 (95% CI –21.62 to 32.63; P=.6905) in 
subjects with hepatic disorders (n=248), and 14.80 (95% CI 6.51 to 23.09; P=.0005) in those 
without hepatic disorders (n=2678). In subjects with hepatic steatosis (n=152), the placebo-
adjusted mean change from baseline in HOMA-%B with linagliptin was 8.00 (95% CI –8.03 
to 24.03; P=.3255). Similarly, the disposition index improved from baseline to week 24 to a 
greater extent in subjects receiving linagliptin compared with those receiving placebo, with 
the treatment difference significant only in patients without hepatic disorders: placebo-
adjusted mean change from baseline in disposition index with linagliptin of 1.13 (95% CI –
11.94 to 14.21; P=.8651) in patients with hepatic disorders (n=274), and 4.87 (95% CI 0.83 
to 8.92; P=.0183) in those without hepatic disorders (n=3005). In subjects with hepatic 
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steatosis (n=166), the placebo-adjusted mean change from baseline in disposition index with 
linagliptin was 1.90 (95% CI –2.28 to 6.08; P=.3706). 
Mean changes in body weight were minimal. In subjects with hepatic disorders, the 
adjusted mean change from baseline in body weight at week 24 was 0.21 ± 0.19 kg and –0.23 
± 0.28 kg in the linagliptin and placebo groups, respectively; a treatment difference of 0.44 
kg (95% CI –0.20 to 1.08; P=.1753). In subjects without hepatic disorders, the adjusted mean 
change from baseline in body weight at week 24 was –0.03 ± 0.07 kg and –0.21 ± 0.09 kg in 
the linagliptin and placebo groups, respectively; a treatment difference of 0.18 kg (95% CI  
–0.01 to 0.36; P=.0637). In subjects with hepatic steatosis, the adjusted mean change from 
baseline in body weight at week 24 was 0.69 ± 0.34 kg with linagliptin and –0.01 ± 0.43 kg 
with placebo, a treatment difference of 0.70 kg (95% CI –0.12 to 1.52; P=.0933). 
 
3.3. Tolerability and safety 
Approximately 70% of subjects with baseline hepatic disorders reported adverse events 
compared with ~60% of those without baseline hepatic disorders, with little numerical 
difference between the linagliptin and placebo groups in the proportions affected. Similarly, 
there was little difference between groups in the incidence of drug-related adverse events, 
treatment discontinuation because of adverse events, and serious adverse events (Table 2). A 
similar safety profile was seen in the subset of patients with baseline hepatic steatosis (Table 
S4). 
The incidence of investigator-defined hypoglycaemia was lower with linagliptin 
(10.4%) than with placebo (15.9%) in patients with hepatic disorders, as well as those 
without (12.1% and 15.1%, respectively). Severe hypoglycemia occurred in 0.5% and 0% of 
linagliptin- and placebo-treated patients, respectively, with hepatic disorders; and in 0.4% and 
0.6% of linagliptin- and placebo-treated patients, respectively, without hepatic disorders. 
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Pancreatitis occurred in three (0.78%) linagliptin-treated subjects and none receiving placebo 
among those with hepatic disorders, and in one (0.02%) linagliptin patient and one (0.05%) 
placebo patient in those without hepatic disorders. Increases in serum amylase or lipase 
during treatment did not occur in any subjects with baseline hepatic disorders. Among those 
without baseline hepatic disorders, amylase increased in 13 (0.31%) and four (0.18%) 
subjects receiving linagliptin and placebo, respectively, and lipase increased in three (0.14%) 
placebo-treated subjects but no linagliptin-treated subjects. No cases of pancreatic cancer 
occurred. 
After adjusting for time exposed to study drugs, incidence rates of affected subjects 
were similar between the linagliptin and placebo groups except for hypoglycemia, which 
occurred at a higher rate with placebo than linagliptin both in subjects with hepatic disorders 
(29.23 and 22.66 subjects, respectively, per 100 subject-years) and those without (28.83 and 
26.16 subjects, respectively, per 100 subject-years). 
 
3.4. Hepatic safety and function 
During treatment with linagliptin or placebo, adverse events related to the liver (hepatobiliary 
disorders) occurred in 11 of 574 (1.9%) subjects with baseline hepatic disorders and 53 of 
6435 (0.8%) patients without baseline hepatic disorders. In neither group was the incidence 
of on-treatment hepatobiliary disorders substantially different between linagliptin- and 
placebo-treated subjects (Table 2). Liver cancer occurred in one subject, an individual with a 
hepatic disorder who was receiving placebo (0.53% of that treatment group). Acute liver 
failure did not occur in any patient. In the subset of patients with baseline hepatic steatosis, 
on-treatment hepatobiliary disorders occurred in 3 (1.3%) linagliptin-treated subjects (all 
hepatic steatosis) and 1 (0.9%) placebo-treated subject (Table S4). 
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Among subjects with baseline hepatic disorders, elevations in transaminases (AST, 
ALT) during treatment were rare, with the proportion affected similar for the linagliptin and 
placebo groups (Table S5). Similarly, ALP, gamma-glutamyl transferase, lactate 
dehydrogenase, and bilirubin were only rarely elevated during treatment with study drug, 
with few discernible differences between linagliptin and placebo subjects (Table S4). No 
Hy’s Law cases (Food & Drug Administration 2009) were observed. 
Mean values for serum lipid levels (total cholesterol, low-density lipoprotein 
cholesterol, high-density lipoprotein cholesterol and triglycerides) did not change 
substantially in any treatment group (data not shown). 
 
4. Discussion 
This retrospective pooled analysis suggests that linagliptin elicits clinically meaningful 
improvements in glycemic control and is well tolerated in people with T2DM and co-existing 
liver disease, a prevalent yet understudied patient population. The improvements in HbA1c, 
FPG and postprandial glucose in patients with baseline hepatic disorders were of similar 
magnitudes to those in patients without baseline hepatic disorders. Furthermore, linagliptin 
demonstrated similar glycemic efficacy and tolerability in the subgroup of subjects with 
hepatic steatosis at baseline. 
The liver is one of the main organs involved in glucose metabolism, and there appears 
to be a bidirectional relationship between diabetes and liver disease. It is estimated that the 
majority of people with T2DM also have NAFLD, the most common type of liver disease 
(Firneisz, 2014; Fruci et al., 2013). Furthermore, in a large population-based cohort study (the 
Verona Diabetes Study), cirrhosis was more than twice as common in people with T2DM 
compared with the general population, and was the fourth leading cause of mortality (de 
Marco et al., 1999). Conversely, it has been estimated that approximately one-third of people 
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with cirrhosis also have T2DM (Tolman et al., 2007). Due to this complex two-way 
relationship, which may be explained by a common etiology previously suggested to be 
insulin resistance (Leite et al., 2014), people with both T2DM and liver disease comprise a 
highly prevalent population. 
The presence of liver disease complicates treatment selection for those with T2DM, 
given the role played by the liver in both glucose homeostasis and metabolism of many 
glucose-lowering drugs. However, relatively few studies of glucose-lowering drugs have 
been conducted exclusively in T2DM subjects with concomitant liver disease, particularly 
with older agents. Almost no pharmacokinetic studies of metformin, sulfonylureas, 
meglitinides or thiazolidinediones in subjects with hepatic impairment have been published 
(Scheen, 2014a). While metformin does not undergo either hepatic metabolism or excretion, 
caution with its use in patients with liver disease is recommended to mitigate the risk of lactic 
acidosis (Khan et al., 2012). Most sulfonylureas are metabolized by the liver and, in the 
absence of pharmacokinetic studies in subjects with hepatic impairment, caution is advised 
for their use in the presence of liver disease in order to reduce the risk of hypoglycemia 
(Scheen, 2014a). Meglitinides are extensively metabolized by the liver and consequently their 
pharmacokinetics are altered by hepatic impairment, with caution therefore advised for their 
use in those with liver disease (Scheen, 2014a). Pioglitazone is also extensively metabolized 
and excreted by the liver; therefore, it is recommended to obtain liver function tests prior to 
and after commencing treatment with pioglitazone and to use it cautiously in the presence of 
liver disease (Khan et al., 2012). Caution, and possible dose reduction, is also advised when 
using insulin in those with hepatic dysfunction because of the risk of hypoglycemia (Khan et 
al., 2012; Scheen, 2014a). 
In contrast to the general lack of published pharmacokinetic data for older glucose-
lowering drugs in hepatic impairment, the newer DPP-4 inhibitors, glucagon-like peptide-1 
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receptor agonists and sodium glucose co-transporter 2 inhibitors have been extensively 
characterized in this setting (Scheen, 2014a; Scheen, 2014b). Of the other globally available 
DPP-4 inhibitors, sitagliptin, vildagliptin, saxagliptin and alogliptin are excreted by the 
kidney with vildagliptin and saxagliptin metabolized extensively by the liver, unlike 
sitagliptin and alogliptin which undergo minimal hepatic metabolism (Scheen, 2014a; 
Scheen, 2014b). Pharmacokinetic studies conducted in subjects with hepatic impairment 
indicate that dose adjustment of these DPP-4 inhibitors is generally not required in the 
presence of hepatic impairment (Scheen, 2014a; Scheen, 2014b) although vildagliptin is not 
recommended for such use (Novartis Pharmaceuticals UK Ltd, 2012). In contrast to other 
DPP-4 inhibitors, linagliptin is excreted extensively by the liver, albeit with only minimal 
hepatic metabolism (Blech et al., 2010; Fuchs et al., 2012). Despite this, a pharmacokinetic 
study in subjects with hepatic impairment found no clinically relevant changes in linagliptin 
exposure, even in those with severely impaired liver function (Graefe-Mody et al., 2012b) – 
the possible reasons for this were discussed earlier. Consequently, dose adjustment of 
linagliptin is not required for any degree of hepatic impairment (Boehringer Ingelheim 
International GmbH & Co. KG, 2013a; McGill et al., 2013).  
For older and newer glucose-lowering drugs alike, there is little published data from 
randomized clinical trials on their glycemic efficacy and tolerability in individuals with liver 
disease (Scheen, 2014a). The pooled analysis of linagliptin reported here addresses this 
evidence gap. This analysis suggests that linagliptin in people with both T2DM and liver 
disease without elevated hepatic enzymes is efficacious and well tolerated across the 
treatment continuum; i.e., as monotherapy, combined with other oral glucose-lowering drugs, 
or added to insulin. In addition, the glucose-lowering efficacy of linagliptin in T2DM patients 
with liver disease was evident across different populations, including various racial/ethnic 
groups, the elderly, those with renal impairment and those intolerant of metformin. 
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Importantly, the presence of liver disease did not affect the glycemic response to linagliptin 
treatment. Linagliptin was also well tolerated, with similar proportions of the linagliptin and 
placebo groups experiencing adverse events. Notably, hypoglycemia affected fewer 
linagliptin-treated subjects than placebo-treated subjects. There is growing recognition that 
hypoglycemia in individuals with T2DM is not a trivial complication, and that preventing or 
minimizing hypoglycemic events may be as important as achieving tight glycemic control in 
vulnerable individuals (Seaquist et al., 2013; Slomski, 2013). 
Importantly, there was no indication that linagliptin adversely impacted pre-existing 
liver disease. There were no cases of acute liver failure, and the incidence of new-onset 
hepatobiliary disorders was low in both the linagliptin and placebo groups (~2%) – albeit 
slightly higher than in subjects without liver disease (~1%). Furthermore, during linagliptin 
treatment, abnormal liver function tests were rare in subjects with baseline hepatic disorders 
as well as those without such disorders. 
This pooled analysis has certain strengths and limitations. Notably, it included data 
for a large number of participants from rigorously controlled clinical trials. However, its post-
hoc nature introduces the potential for confounding bias, as subjects were not randomized 
specifically for the analysis. Nevertheless, the baseline clinical and demographic 
characteristics of subjects were similar between treatment groups. Importantly, the presence 
or absence of hepatic disorders at baseline was identified by self-reporting with no formal 
assessment for liver disease, and subjects with active hepatic disease (serum transaminases 
>3 times ULN) were excluded. Of note, the study population had a heterogenous group of 
liver disorders. Moreover, linagliptin was compared only with placebo and not with other 
glucose-lowering drugs, and the demographic and clinical characteristics of the subjects in 
this analysis may not be identical to those with T2DM and liver disease elsewhere in clinical 
practice. 
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In conclusion, this large retrospective pooled analysis of 17 randomized clinical trials 
provides evidence that linagliptin – an enterohepatically excreted DPP-4 inhibitor that does 
not require dose adjustment for hepatic impairment – is efficacious and well tolerated in 
individuals with T2DM and concomitant liver disease. In addition, there was no evidence that 
liver disease either affected the glycemic response to linagliptin or was adversely impacted 
by linagliptin. Linagliptin, therefore, may be a useful option within the therapeutic 
armamentarium for people with T2DM and liver disease, given the constraints on other 
glucose-lowering drugs in this under-recognised and prevalent population. 
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Tables and Figures 
Table 1 
Baseline demographic and clinical characteristics 
 Hepatic disorders No hepatic disorders 
Linagliptin Placebo Linagliptin Placebo 
Treated set, n 385 189 4240 2195 
Male, n (%) 219 (56.9) 119 (63.0) 2240 (52.8) 1174 (53.5) 
Age, years 57.5 ± 10.3 57.6 ± 10.0 58.4 ± 10.7 58.8 ± 10.7 
<65 years, n (%) 286 (74.3) 144 (76.2) 2976 (70.2) 1512 (68.9) 
65 to 74 years, n (%) 87 (22.6) 38 (20.1) 1011 (23.8) 537 (24.5) 
≥75 years, n (%) 12 (3.1) 7 (3.7) 253 (6.0) 146 (6.7) 
Race, n (%)     
White 192 (49.9) 100 (52.9) 2356 (55.6) 1243 (56.6) 
Asian 185 (48.1) 81 (42.9) 1700 (40.1) 780 (35.5) 
Black 8 (2.1) 8 (4.2) 184 (4.3) 172 (7.8) 
BMI, kg/m
2
 29.3 ± 5.2 29.7 ± 5.4 29.0 ± 5.2 29.6 ± 5.3 
Renal function (eGFR, ml/min/1.73 
m
2
)*, n (%) 
    
Normal (≥90) 150 (39.0) 78 (41.3) 1690 (39.9) 801 (35.6) 
Mild impairment (60 to <90) 191 (49.6) 79 (41.8) 1976 (46.6) 997 (45.4) 
Moderate impairment (30 to <60) 37 (9.6) 21 (11.1) 460 (10.8) 281 (12.8) 
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 Hepatic disorders No hepatic disorders 
Linagliptin Placebo Linagliptin Placebo 
Severe impairment (<30) 7 (1.8) 11 (5.8) 104 (2.5) 101 (4.6) 
Missing data 0 (0) 0 (0) 10 (0.2) 15 (0.7) 
Liver function, median 
(interquartile range) 
    
AST (GOT)
†
, units/l 24 (15−42) 27 (19−39) 18 (11−27) 18 (12−27) 
ALT (SGPT)
‡
, units/l 32 (20−59) 34 (20−54) 23 (14−36) 22 (14−34) 
ALP
§
, units/l 138 (105−181) 149 (112−189) 135 (103−176) 137 (103−181) 
GGT
II
, units/l 50 (27−98) 50 (23−92) 28 (15−51) 27 (13−51) 
LDH
¶
, units/l 169 (142−190) 166 (140−197) 169 (144−192) 171 (144−196) 
Bilirubin**, mg/dl 0.4 (0.3−0.6) 0.4 (0.2−0.6) 0.4 (0.2−0.5) 0.3 (0.2−0.5) 
Full-analysis set, n 378 188 4154 2138 
HbA1c, % 
(mmol/mol) 
8.23 ± 0.85 
(66.49 ± 0.48) 
8.25 ± 0.91 
(66.65 ± 0.73) 
8.17 ± 0.87 
(65.82 ± 0.15) 
8.22 ± 0.89 
(66.28 ± 0.21) 
Fasting plasma glucose, mmol/l 9.15 ± 2.37 9.21 ± 2.63 9.06 ± 2.47 9.05 ± 2.59 
Diabetes duration, n (%)     
≤1 year 46 (12.2) 23 (12.2) 549 (13.2) 244 (11.4) 
>1 to ≤5 years 118 (31.2) 43 (22.9) 1231 (29.6) 553 (25.9) 
>5 years 214 (56.6) 122 (64.9) 2374 (57.1) 1341 (62.7) 
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 Hepatic disorders No hepatic disorders 
Linagliptin Placebo Linagliptin Placebo 
Glucose-lowering drugs at 
screening, n (%) 
    
0 78 (20.6) 34 (18.1) 645 (15.5) 332 (15.5) 
1 108 (28.6) 58 (30.9) 1622 (39.0) 809 (37.8) 
≥2 192 (50.8) 96 (51.1) 1887 (45.4) 997 (46.6) 
Data are mean ± SD unless otherwise stated. AST, aspartate transaminase/aspartate aminotransferase; 
ALP, alkaline phosphatase; ALT, alanine transaminase/alanine aminotransferase; eGFR, estimated 
glomerular filtration rate; GGT, gamma-glutamyl transferase; GOT, serum glutamic oxaloacetic 
transaminase; LDH, lactate dehydrogenase; SGPT, serum glutamate-pyruvate transaminase/serum 
glutamic-pyruvic transaminase. 
*According to the Modification of Diet in Renal Disease study equation. 
†
Data are for subjects in the treated set with available baseline measurements. Hepatic disorders: 372 
linagliptin, 185 placebo; no hepatic disorders: 4090 linagliptin, 2099 placebo. 
‡
Hepatic disorders: 372 linagliptin, 185 placebo; no hepatic disorders: 4091 linagliptin, 2100 placebo. 
§
Hepatic disorders: 373 linagliptin, 186 placebo; no hepatic disorders: 4106 linagliptin, 2105 placebo. 
II
Hepatic disorders: 368 linagliptin, 184 placebo; no hepatic disorders: 4004 linagliptin, 1987 placebo. 
¶
Hepatic disorders: 363 linagliptin, 182 placebo; no hepatic disorders: 3966 linagliptin, 1970 placebo. 
**Hepatic disorders: 367 linagliptin, 178 placebo; no hepatic disorders: 4038 linagliptin, 2044 placebo. 
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Table 2 
Adverse events 
 Hepatic disorders No hepatic disorders 
Linagliptin 
(n=385) 
Placebo 
(n=189) 
Linagliptin 
(n=4240) 
Placebo 
(n=2195) 
Subjects, n (%) 
Any AE 269 (69.9) 130 (68.8) 2413 (56.9) 1376 (62.7) 
Drug-related AE 52 (13.5) 28 (14.8) 492 (11.6) 303 (13.8) 
Serious AE 29 (7.5) 16 (8.5) 200 (4.7) 149 (6.8) 
Death 0 (0) 0 (0) 10 (0.2) 9 (0.4) 
Requiring hospitalization 29 (7.5) 14 (7.4) 184 (4.3) 125 (5.7) 
AE leading to discontinuation 16 (4.2) 5 (2.6) 116 (2.7) 86 (3.9) 
Hepatobiliary disorders* 8 (2.1) 3 (1.6) 33 (0.8) 20 (0.9) 
Hepatic steatosis
†
 5 (1.3) 1 (0.5) 11 (0.3) 6 (0.3) 
Liver disorder
†
 2 (0.5) 0 (0) 0 (0) 0 (0) 
Biliary dilatation
†
 1 (0.3) 0 (0) 0 (0) 0 (0) 
Gallbladder polyp
†
 1 (0.3) 0 (0) 2 (0.1) 1 (0.1) 
Hepatic fibrosis
†
 1 (0.3) 0 (0) 0 (0) 0 (0) 
Granulomatous liver 
disease
†
 
1 (0.3) 0 (0) 0 (0) 0 (0) 
Other
‡
 0 (0) 2 (1.1) 24 (0.6) 19 (0.9) 
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 Hepatic disorders No hepatic disorders 
Linagliptin 
(n=385) 
Placebo 
(n=189) 
Linagliptin 
(n=4240) 
Placebo 
(n=2195) 
Incidence rate (subjects affected per 100 subject-years)
§
 
Any AE 283.43 251.84 195.10 210.84 
Drug-related AE 29.36 27.01 24.23 25.07 
Serious AE 15.16 14.14 9.21 11.43 
Death 0 0 0.45 0.66 
Requiring hospitalization 15.14 12.32 8.46 9.57 
AE leading to discontinuation 7.99 4.20 5.20 6.35 
Hepatobiliary disorders* 4.08 2.55 1.48 1.48 
Hepatic steatosis
†
 2.52 0.85 0.49 0.44 
Liver disorder
†
 1.00 0 0 0 
Biliary dilatation
†
 0.50 0 0 0 
Gallbladder polyp
†
 0.50 0 0.09 0.07 
Hepatic fibrosis
†
 0.50 0 0 0 
Granulomatous liver 
disease
†
 
0.50 0 0 0 
Data are for the treated set of patients. 
AE, adverse event. 
*System organ class from the Medical Dictionary for Regulatory Activities (MedDRA) 
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 Hepatic disorders No hepatic disorders 
Linagliptin 
(n=385) 
Placebo 
(n=189) 
Linagliptin 
(n=4240) 
Placebo 
(n=2195) 
version 15.1; subjects may have experienced >1 individual AE (preferred term). 
†
Preferred term from MedDRA. 
‡
Sum of the number of subjects experiencing other preferred terms under the hepatobiliary 
disorders system organ class. 
§
Calculated by dividing the number of subjects with the event by the time at risk expressed as 
100 subject-years. 
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Figure captions 
Fig. 1. Adjusted mean change from baseline in HbA1c at week 24. Data are for the full-
analysis set of participants (LOCF). 
Fig. 2. Change from baseline in HbA1c over time. Data are for the full-analysis set of 
participants (LOCF). 
Fig. 3. Change from baseline in HbA1c at week 24 by (A) duration of T2DM, (B) renal 
function and (C) race. eGFR, estimated glomerular filtration rate. Data are for the full-
analysis set of participants (LOCF). 
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Figures  
Fig. 1. Adjusted mean change from baseline in HbA1c at week 24. Data are for the full-
analysis set of participants (LOCF). 
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Fig. 2. Change from baseline in HbA1c over time. Data are for the full-analysis set of 
participants (LOCF). 
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Fig. 3. Change from baseline in HbA1c at week 24 by (A) duration of T2DM; (B) renal function and (C) race. eGFR, estimated glomerular 
filtration rate. Data are for the full-analysis set of participants (LOCF). 
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Online-Only Supporting Information 
Table S1 
Randomized, double-blind, placebo-controlled Phase II or III clinical trials of linagliptin that included participants with hepatic disorders at 
baseline 
ClinicalTrials.gov 
number 
Participant population Treatment regimen (linagliptin or 
placebo) 
Primary 
endpoint 
(week) 
Baseline hepatic 
disorders, treated set (n) 
Reference 
Yes No 
NCT00621140 Aged 18–80 years Monotherapy 24 29 474 (Del Prato et al., 
2011) 
NCT00641043 Aged 18–80 years Initial combination with 
pioglitazone 
24 47 342 (Gomis et al., 2011) 
NCT00601250 Aged 18–80 years Added to metformin 24 34 666 (Taskinen et al., 
2011) 
NCT00602472 Aged 18–80 years Added to metformin and a 
sulfonylurea 
24 126 929 (Owens et al., 
2011) 
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ClinicalTrials.gov 
number 
Participant population Treatment regimen (linagliptin or 
placebo) 
Primary 
endpoint 
(week) 
Baseline hepatic 
disorders, treated set (n) 
Reference 
Yes No 
NCT00654381 Aged 20–80 years in Japan Monotherapy 12 72 167 (Kawamori et al., 
2012) 
NCT00819091 Aged 18–80 years Added to a sulfonylurea 18 13 225 (Lewin et al., 2012) 
NCT00954447 Aged ≥18 years Added to basal insulin 24 114 1141 (Yki-Järvinen et al., 
2013) 
NCT00800683 Aged 18–80 years with severe renal 
impairment 
Added to other glucose-lowering 
drugs 
12 9 121 (McGill et al., 
2013) 
NCT00798161 Aged 18–80 years Initial combination with metformin 24 21 193 (Haak et al., 2012) 
NCT00740051 Aged 18–80 years with metformin 
intolerance/contraindication 
Monotherapy 18 12 215 (Barnett et al., 
2012) 
NCT00996658 Aged 18–79 years Added to metformin and 
pioglitazone 
24 12 260 (Bajaj et al., 2014) 
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ClinicalTrials.gov 
number 
Participant population Treatment regimen (linagliptin or 
placebo) 
Primary 
endpoint 
(week) 
Baseline hepatic 
disorders, treated set (n) 
Reference 
Yes No 
NCT01012037 Aged 18–80 years Added to metformin 12 30 461 (Ross et al., 2012) 
NCT01084005 Aged ≥70 years Added to metformin and/or a 
sulfonylurea and/or basal insulin 
24 4 237 (Barnett et al., 
2013) 
NCT01087502 Aged ≥18 years with 
moderate/severe renal impairment 
Added to other glucose-lowering 
drugs or monotherapy 
12 24 211 (Laakso et al., 
2015) 
NCT01215097 Aged 18–80 years in Asia Added to metformin 24 7 298 (Wang et al., 2015) 
NCT01214239 Aged 18–80 years in Asia Monotherapy 24 14 285 (Chen et al., 2015) 
NCT01194830 Black/African American subjects 
aged 18–80 years 
Monotherapy or added to one 
glucose-lowering drug 
24 6 210 (Thrasher et al., 
2014) 
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Table S2 
Definition of pancreatic adverse events 
Adverse event Definition 
Pancreatitis Either the MedDRA preferred term of “chronic pancreatitis” or any of the preferred terms from the Standardized 
MedDRA Query for pancreatitis based on MedDRA version 17.0: Cullen’s sign, hereditary pancreatitis, ischemic 
pancreatitis, edematous pancreatitis, pancreatic abscess, pancreatic hemorrhage, pancreatic necrosis, pancreatic 
phlegmon, pancreatic pseudocyst, pancreatic pseudocyst drainage, pancreatitis, pancreatitis acute, pancreatitis 
hemorrhagic, pancreatitis necrotizing, pancreatitis relapsing, pancreatorenal syndrome. 
Pancreatic cancer Any of the following preferred terms from MedDRA version 17.0: acinar cell carcinoma of pancreas, adenocarcinoma 
pancreas, benign neoplasm of islets of Langerhans, benign pancreatic neoplasm, carcinoid tumor of the pancreas, 
ductal adenocarcinoma of pancreas, glucagonoma, insulinoma, intraductal papillary mucinous neoplasm, intraductal 
papillary mucinous carcinoma of pancreas, malignant neoplasm of islets of Langerhans, mucinous 
cystadenocarcinoma of pancreas, multiple endocrine neoplasia, multiple endocrine neoplasia type 1, multiple 
endocrine neoplasia type 2, multiple endocrine neoplasia type 2a, multiple endocrine neoplasia type 2b, 
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Adverse event Definition 
neuroendocrine carcinoma, neurotensinoma, pancreatic carcinoma, pancreatic carcinoma metastatic, pancreatic 
carcinoma recurrent, pancreatic carcinoma stage 0, pancreatic carcinoma stage I, pancreatic carcinoma stage II, 
pancreatic carcinoma stage III, pancreatic carcinoma stage IV, pancreatic neoplasm, pancreatic neuroendocrine tumor, 
pancreatic neuroendocrine tumor metastatic, pancreatic sarcoma, Peutz–Jeghers syndrome, serous 
cystadenocarcinoma of pancreas, solid pseudopapillary tumor of the pancreas, somatostatinoma, vipoma. 
MedDRA, Medical Dictionary for Regulatory Activities 
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Table S3 
Participants with hepatic disorders at baseline 
 Linagliptin 
(n=385) 
Placebo 
(n=189) 
Concomitant diagnosis at baseline 374 (97.1) 183 (96.8) 
Hepatic steatosis 230 (59.7) 113 (59.8) 
Liver disorder 22 (5.7) 13 (6.9) 
Hepatic enzyme increased 14 (3.6) 7 (3.7) 
Gamma-glutamyl transferase increased 12 (3.1) 3 (1.6) 
Hepatomegaly 14 (3.6) 5 (2.6) 
Chronic hepatitis 10 (2.6) 4 (2.1) 
Hepatitis B 9 (2.3) 7 (3.7) 
Hepatitis C 9 (2.3) 5 (2.6) 
Hepatitis A 9 (2.3) 2 (1.1) 
Alcoholic liver disease 8 (2.1) 2 (1.1) 
Hepatic cyst 7 (1.8) 3 (1.6) 
Hepatic function abnormal 6 (1.6) 2 (1.1) 
Alanine aminotransferase increased 6 (1.6) 1 (0.5) 
Non-alcoholic steatohepatitis 5 (1.3) 6 (3.2) 
Liver function test abnormal 5 (1.3) 5 (2.6) 
Chronic hepatitis B 5 (1.3) 0 (0) 
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 Linagliptin 
(n=385) 
Placebo 
(n=189) 
Hemangioma of liver 4 (1.0) 1 (0.5) 
Viral hepatitis carrier 4 (1.0) 0 (0) 
Aspartate aminotransferase increased 4 (1.0) 0 (0) 
Jaundice 3 (0.8) 2 (1.1) 
Hypoalbuminemia 3 (0.8) 0 (0) 
Hepatitis alcoholic 3 (0.8) 0 (0) 
Chronic hepatitis C 3 (0.8) 0 (0) 
Blood alkaline phosphatase increased 2 (0.5) 2 (1.1) 
Liver injury 2 (0.5) 1 (0.5) 
Hepatitis infectious 2 (0.5) 1 (0.5) 
Fatty liver alcoholic 2 (0.5) 0 (0) 
Autoimmune hepatitis 2 (0.5) 0 (0) 
Hepatitis 1 (0.3) 3 (1.6) 
Hepatic cirrhosis 1 (0.3) 2 (1.1) 
Ascites 1 (0.3) 1 (0.5) 
Hepatic fibrosis 1 (0.3) 1 (0.5) 
Hepatitis viral 1 (0.3) 1 (0.5) 
Hepatosplenomegaly 1 (0.3) 1 (0.5) 
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 Linagliptin 
(n=385) 
Placebo 
(n=189) 
Cirrhosis alcoholic 1 (0.3) 0 (0) 
Hepatic echinococciasis 1 (0.3) 0 (0) 
Hepatic enzyme abnormal 1 (0.3) 0 (0) 
Liver abscess 1 (0.3) 0 (0) 
Hepatic mass 1 (0.3) 0 (0) 
Hepatitis neoplasm 1 (0.3) 0 (0) 
Hepatitis neoplasm malignant 1 (0.3) 0 (0) 
Transaminases increased 1 (0.3) 0 (0) 
Yellow skin 1 (0.3) 0 (0) 
Blood bilirubin increased 0 (0) 1 (0.5) 
Glycogen storage disease type 1 1 (0.3) 0 (0) 
Hepatectomy 0 (0) 1 (0.5) 
Hepatic adenoma 0 (0) 1 (0.5) 
Hepatitis chronic active 0 (0) 1 (0.5) 
Hyperbilirubinemia 0 (0) 1 (0.5) 
Cryptogenic cirrhosis 0 (0) 2 (1.1) 
Varices esophageal 0 (0) 2 (1.1) 
Adverse event at baseline* 15 (3.9) 9 (4.8) 
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 Linagliptin 
(n=385) 
Placebo 
(n=189) 
Alanine aminotransferase increased 7 (1.8) 2 (1.1) 
Aspartate aminotransferase increased 4 (1.0) 0 (0) 
Blood bilirubin increased 2 (0.5) 0 (0) 
Hepatic enzyme increased 1 (0.3) 1 (0.5) 
Blood alkaline phosphatase increased 1 (0.3) 0 (0) 
Hemangioma of liver 1 (0.3) 0 (0) 
Hepatomegaly 1 (0.3) 0 (0) 
Hypoalbuminemia 1 (0.3) 0 (0) 
Liver injury 1 (0.3) 0 (0) 
Gamma-glutamyl transferase increased 0 (0) 3 (1.6) 
Jaundice cholestatic 0 (0) 1 (0.5) 
Hepatic neoplasm 0 (0) 1 (0.5) 
Hepatocellular injury 0 (0) 1 (0.5) 
Data are n (%) of the treated set of participants. Categories are not mutually exclusive 
(participants could have had both a concomitant diagnosis and adverse event at 
baseline, and could have had more than one hepatic disorder within each category). 
Disorders shown are preferred terms in the Standardized Medical Query “hepatic 
disorders” from the Medical Dictionary for Regulatory Activities version 15.1. 
*Adverse events reported at screening prior to initiation of study drug. 
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Table S4 
Adverse events in subjects with baseline hepatic disorders with or without baseline hepatic 
steatosis 
 Hepatic steatosis No hepatic steatosis 
Linagliptin 
(n=230) 
Placebo 
(n=113) 
Linagliptin 
(n=155) 
Placebo 
(n=76) 
Subjects, n (%) 
Any AE 159 (69.1) 77 (68.1) 110 (71.0) 53 (69.7) 
Drug-related AE 22 (9.6) 14 (12.4) 30 (19.4) 14 (18.4) 
Serious AE 23 (10.0) 7 (6.2) 6 (3.9) 9 (11.8) 
Death 0 0 0 0 
Requiring hospitalization 23 (10.0) 5 (4.4) 6 (3.9) 9 (11.8) 
AE leading to discontinuation 12 (5.2) 1 (0.9) 4 (2.6) 4 (5.3) 
Hepatobiliary disorders* 3 (1.3) 1 (0.9) 5 (3.2) 2 (2.6) 
Hepatic steatosis
†
 3 (1.3) 0 2 (1.3) 1 (1.3) 
Hepatic fibrosis
†
 1 (0.4) 0 0 0 
Liver disorder
†
 0 0 2 (1.3) 0 
Biliary dilatation
†
 0 0 1 (0.7) 0 
Gallbladder polyp
†
 0 0 1 (0.7) 0 
Granulomatous liver 
disease
†
 
0 0 1 (0.7) 0 
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 Hepatic steatosis No hepatic steatosis 
Linagliptin 
(n=230) 
Placebo 
(n=113) 
Linagliptin 
(n=155) 
Placebo 
(n=76) 
Other
‡
 0 1 (0.9) 0 1 (1.3) 
Incidence rate (subjects affected per 100 subject-years)
§
 
Any AE 285.07 239.36 281.10 272.50 
Drug-related AE 19.78 23.02 45.51 32.68 
Serious AE 20.30 10.55 7.69 19.25 
Death 0 0 0 0 
Requiring hospitalization 20.26 7.48 7.69 19.25 
AE leading to discontinuation 10.08 1.46 4.93 7.89 
Hepatobiliary disorders*     
Hepatic steatosis
†
 2.55 0 2.48 2.02 
Hepatic fibrosis
†
 0.84 0 0 0 
Liver disorder
†
 0 0 2.51 0 
Biliary dilatation
†
 0 0 1.23 0 
Gallbladder polyp
†
 0 0 1.23 0 
Granulomatous liver 
disease
†
 
0 0 1.24 0 
Data are for the treated set of patients. 
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 Hepatic steatosis No hepatic steatosis 
Linagliptin 
(n=230) 
Placebo 
(n=113) 
Linagliptin 
(n=155) 
Placebo 
(n=76) 
AE, adverse event. 
*System organ class from the Medical Dictionary for Regulatory Activities (MedDRA) 
version 15.1; subjects may have experienced >1 individual AE (preferred term). 
†
Preferred term from MedDRA. 
‡
Sum of the number of subjects experiencing other preferred terms under the hepatobiliary 
disorders system organ class. 
§
Calculated by dividing the number of subjects with the event by the time at risk expressed as 
100 subject-years. 
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Table S5 
On-treatment changes in levels of hepatic enzymes and bilirubin in subjects with hepatic disorders 
Baseline Last value on treatment Minimum value on 
treatment 
Maximum value on 
treatment 
 
<LLN LLN–ULN >ULN ≥LLN <LLN ≤ULN >ULN Total 
AST (GOT)         
Placebo (n=189)         
<LLN 0 1 (100.0) 0 0 0 1 (100.0) 0 1 (100.0) 
LLN–ULN 0 153 (95.0) 8 (5.0) 161 (100.0) 0 161 (100.0) 18 (11.2) 161 (100.0) 
>ULN 0 10 (43.5) 13 (56.5) 23 (100.0) 0 0 0 23 (100.0) 
Total 0 164 (88.6) 21 (11.4) 184 (99.5) 0 162 (87.6) 18 (9.7) 185 (100.0) 
Linagliptin (n=385)         
<LLN 0 0 0 0 0 0 0 0 
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Baseline Last value on treatment Minimum value on 
treatment 
Maximum value on 
treatment 
 
<LLN LLN–ULN >ULN ≥LLN <LLN ≤ULN >ULN Total 
LLN–ULN 0 292 (94.8) 16 (5.2) 308 (100.0) 0 308 (100.0) 30 (9.7) 308 (100.0) 
>ULN 0 27 (42.2) 37 (57.8) 64 (100.0) 0 0 0 64 (100.0) 
Total 0 319 (85.8) 53 (14.2) 372 (100.0) 0 308 (82.8) 30 (8.1) 372 (100.0) 
ALT (SGPT)         
Placebo (n=189)         
<LLN 0 1 (100.0) 0 0 0 1 (100.0) 0 1 (100.0) 
LLN–ULN 0 130 (92.2) 11 (7.8) 141 (100.0) 0 141 (100.0) 20 (14.2) 141 (100.0) 
>ULN 0 21 (48.8) 22 (51.2) 43 (100.0) 0 0 0 43 (100.0) 
Total 0 152 (82.2) 33 (17.8) 184 (99.5) 0 142 (76.8) 20 (10.8) 185 (100.0) 
Linagliptin (n=385)         
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Baseline Last value on treatment Minimum value on 
treatment 
Maximum value on 
treatment 
 
<LLN LLN–ULN >ULN ≥LLN <LLN ≤ULN >ULN Total 
<LLN 0 0 0 0 0 0 0 0 
LLN–ULN 0 254 (93.0) 19 (7.0) 273 (100.0) 0 273 (100.0) 33 (12.1) 273 (100.0) 
>ULN 0 38 (38.4) 61 (61.6) 99 (100.0) 0 0 0 99 (100.0) 
Total 0 292 (78.5) 80 (21.5) 372 (100.0) 0 273 (73.4) 33 (8.9) 372 (100.0) 
ALP         
Placebo (n=189)         
<LLN 1 (100.0) 0 0 0 0 1 (100.0) 0 1 (100.0) 
LLN–ULN 1 (0.6) 163 (95.9) 6 (3.5) 170 (100.0) 1 (0.6) 170 (100.0) 10 (5.9) 170 (100.0) 
>ULN 0 3 (20.0) 12 (80.0) 15 (100.0) 0 0 0 15 (100.0) 
Total 2 (1.1) 166 (89.2) 18 (9.7) 185 (99.5) 1 (0.5) 171 (91.9) 10 (5.4) 186 (100.0) 
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Baseline Last value on treatment Minimum value on 
treatment 
Maximum value on 
treatment 
 
<LLN LLN–ULN >ULN ≥LLN <LLN ≤ULN >ULN Total 
Linagliptin (n=385)         
<LLN 4 (44.4) 5 (55.6) 0 0 0 9 (100.0) 0 9 (100.0) 
LLN–ULN 5 (1.5) 332 (97.6) 3 (0.9) 340 (100.0) 7 (2.1) 340 (100.0) 8 (2.4) 340 (100.0) 
>ULN 0 10 (41.7) 14 (58.3) 24 (100.0) 0 0 0 24 (100.0) 
Total 9 (2.4) 347 (93.0) 17 (4.6) 364 (97.6) 7 (2.1) 349 (93.6) 8 (2.1) 373 (100.0) 
GGT         
Placebo (n=189)         
<LLN 0 0 0 0 0 0 0 0 
LLN–ULN 1 (0.8) 116 (89.2) 13 (10.0) 130 (100.0) 1 (0.8) 130 (100.0) 16 (12.3) 130 (100.0) 
>ULN 0 16 (29.6) 38 (70.4) 54 (100.0) 0 0 0 54 (100.0) 
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Baseline Last value on treatment Minimum value on 
treatment 
Maximum value on 
treatment 
 
<LLN LLN–ULN >ULN ≥LLN <LLN ≤ULN >ULN Total 
Total 1 (0.5) 132 (71.7) 51 (27.7) 184 (100.0) 1 (0.5) 130 (70.7) 16 (8.7) 184 (100.0) 
Linagliptin (n=385)         
<LLN 1 (100.0) 0 0 0 0 1 (100.0) 0 1 (100.0) 
LLN–ULN 0 236 (92.2) 20 (7.8) 256 (100.0) 2 (0.8) 256 (100.0) 30 (11.7) 256 (100.0) 
>ULN 0 14 (12.6) 97 (87.4) 111 (100.0) 0 0 0 111 (100.0) 
Total 1 (0.3) 250 (67.9) 117 (31.8) 367 (99.7) 2 (0.5) 257 (69.8) 30 (8.2) 368 (100.0) 
LDH         
Placebo (n=189)         
<LLN 8 (61.5) 5 (38.5) 0 0 0 13 (100.0) 0 13 (100.0) 
LLN–ULN 6 (3.9) 141 (92.8) 5 (3.3) 152 (100.0) 21 (13.8) 152 (100.0) 7 (4.6) 152 (100.0) 
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Baseline Last value on treatment Minimum value on 
treatment 
Maximum value on 
treatment 
 
<LLN LLN–ULN >ULN ≥LLN <LLN ≤ULN >ULN Total 
>ULN 0 5 (29.4) 12 (70.6) 17 (100.0) 0 0 0 17 (100.0) 
Total 14 (7.7) 151 (83.0) 17 (9.3) 169 (92.9) 21 (11.5) 165 (90.7) 7 (3.8) 182 (100.0) 
Linagliptin (n=385)         
<LLN 14 (35.9) 25 (64.1) 0 0 0 39 (100.0) 0 39 (100.0) 
LLN–ULN 15 (4.9) 284 (92.5) 8 (2.6) 307 (100.0) 25 (8.1) 307 (100.0) 26 (8.5) 307 (100.0) 
>ULN 0 4 (23.5) 13 (76.5) 17 (100.0) 0 0 0 17 (100.0) 
Total 29 (8.0) 313 (86.2) 21 (5.8) 324 (89.3) 25 (6.9) 346 (95.3) 26 (7.2) 363 (100.0) 
Bilirubin         
Placebo (n=189)         
<LLN 1 (33.3) 2 (66.7) 0 0 0 3 (100.0) 0 3 (100.0) 
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Baseline Last value on treatment Minimum value on 
treatment 
Maximum value on 
treatment 
 
<LLN LLN–ULN >ULN ≥LLN <LLN ≤ULN >ULN Total 
LLN–ULN 3 (1.8) 156 (95.7) 4 (2.5) 163 (100.0) 11 (6.7) 163 (100.0) 8 (4.9) 163 (100.0) 
>ULN 0 4 (33.3) 8 (66.7) 12 (100.0) 0 0 0 12 (100.0) 
Total 4 (2.2) 162 (91.0) 12 (6.7) 175 (98.3) 11 (6.2) 166 (93.3) 8 (4.5) 178 (100.0) 
Linagliptin (n=385)         
<LLN 1 (20.0) 4 (80.0) 0 0 0 5 (100.0) 0 5 (100.0) 
LLN–ULN 7 (2.0) 326 (95.0) 10 (2.9) 343 (100.0) 20 (5.8) 343 (100.0) 15 (4.4) 343 (100.0) 
>ULN 0 10 (52.6) 9 (47.4) 19 (100.0) 0 0 0 19 (100.0) 
Total 8 (2.2) 340 (92.6) 19 (5.2) 362 (98.6) 20 (5.4) 348 (94.8) 15 (4.1) 367 (100.0) 
Data are n (%) of the treated set of subjects. Bolded data indicate shifts between categories of reference range. AST, aspartate 
transaminase/aspartate aminotransferase; ALP, alkaline phosphatase; ALT, alanine transaminase/alanine aminotransferase; GGT, gamma-
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Baseline Last value on treatment Minimum value on 
treatment 
Maximum value on 
treatment 
 
<LLN LLN–ULN >ULN ≥LLN <LLN ≤ULN >ULN Total 
glutamyl transferase; GOT, serum glutamic oxaloacetic transaminase; LDH, lactate dehydrogenase; LLN, lower limit of normal; SGPT, 
serum glutamate-pyruvate transaminase/serum glutamic-pyruvic transaminase; ULN, upper limit of normal. 
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